Post
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system …
Xilio and Gilead partner up for IL-12 therapeutic development
Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the deal, …
Cheap drugs, inspections, and a future war in Europe – what’s driving drug shortages?
Drug shortages are worsening globally, leaving patients without access to essential medications, and healthcare providers struggling to find alternative treatments. …
Boundless Bio raises $100m as IPO market rouses
US-based Boundless Bio will offer 6,250,000 shares for $16 each as the oncology company hears the bell on the Nasdaq …
OSE Immunotherapeutics gets grant for anti-human SIRPA antibody for treating cancer
OSE Immunotherapeutics has been granted a patent for antibodies targeting human SIRPa, enhancing antigen presentation to T cells. The invention …
Nanoscope Therapeutics exhibits positive top-line Phase IIb results for MCO-010
Nanoscope Therapeutics released promising top-line results for its RESTORE trial, which is studying the gene therapy MCO-010 in patients with …
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
Licensing agreements for innovator drugs utilising clustered regularly interspaced short palindromic repeats (CRISPR) technologies saw oncology, immunology, and central nervous system …
Xilio and Gilead partner up for IL-12 therapeutic development
Gilead Sciences and Xilio Therapeutics declared an exclusive license agreement for the development of a tumour-activated IL-12 program. Under the deal, …
Cheap drugs, inspections, and a future war in Europe – what’s driving drug shortages?
Drug shortages are worsening globally, leaving patients without access to essential medications, and healthcare providers struggling to find alternative treatments. …
Boundless Bio raises $100m as IPO market rouses
US-based Boundless Bio will offer 6,250,000 shares for $16 each as the oncology company hears the bell on the Nasdaq …
OSE Immunotherapeutics gets grant for anti-human SIRPA antibody for treating cancer
OSE Immunotherapeutics has been granted a patent for antibodies targeting human SIRPa, enhancing antigen presentation to T cells. The invention …
Cidara Therapeutics gets grant for conjugates for treating viral infections
Cidara Therapeutics has been granted a patent for compositions and methods for treating viral infections using conjugates containing neuraminidase inhibitors …
Synlogic gets grant for genetically engineered bacteria for treating phenylketonuria
Synlogic has been granted a patent for genetically programmed microorganisms, like bacteria, for modulating and treating diseases. The patent includes …
Abivax gets grant for antitumor pharmaceutical combination for cancer treatment
Abivax has been granted a patent for an antitumor pharmaceutical combination involving compound ABX196 and chemotherapeutic or immunotherapeutic agents for …
4D Molecular Therapeutics gets grant for recombinant aav for muscle cell infectivity with heterologous peptide
4D Molecular Therapeutics has been granted a patent for variant adeno-associated virus (AAV) capsid proteins that increase infectivity of muscle …